depression
Alto Neuroscience announces new patent for depression treatment
January 15, 2026Sales and Marketing Alto Neuroscience, Psychiatry, depression
Alto Neuroscience, a clinical-stage biopharmaceutical company specialising in precision treatments for neuropsychiatric conditions, has announced the issuance of a US …
Study finds at-home brain stimulation therapies reduce depression relapse rate
November 14, 2025Research and Development Brain Stimulation Therapies, Flow Neuroscience, Transcranial Direct Current Stimulation Therapy, depression
A new study published in the Journal of Affective Disorders has found that home-based, transcranial, direct current stimulation (tDCS) therapy, …
NICE recommends nine digital treatment options for depression and anxiety
May 17, 2023Medical Communications NICE, Neurology, anxiety, depression, digital health, mental health
The National Institute for Health and Care Excellence (NICE) has recommended six digitally enabled therapies for adult patients with anxiety …
Perception and Otsuka enter collaboration and licensing deal for depression drug candidate
March 16, 2021Manufacturing and Production CNS, Otsuka Pharmaceutical, Perception Neuroscience, depression
Perception Neuroscience and Otsuka Pharmaceutical have announced a collaboration and licensing agreement for the development and commercialisation of Perception’s lead …
Janssen’s esketamine nasal spray secures CHMP recommendation in Europe for the rapid reduction of depressive symptoms in a psychiatric emergency for patients with major depressive disorder
December 11, 2020Medical Communications EMA, Europe, Spravato, depression
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has moved to recommend Janssen’s …
NICE knocks back Janssen’s Spravato nasal spray for the second time in treatment-resistant depression
September 3, 2020Sales and Marketing Janssen, Spravato, depression, pharma
NICE has opted to reject Janssen’s nasal spray Spravato (esketamine) for routine use on the NHS for treatment-resistant major depressive …
FDA expands approval for Janssen’s Spravato nasal spray to cover major depressive disorder with suicidal ideation
August 4, 2020Manufacturing and Production FDA Janssen, Spravato, depression
The FDA has moved to expand the existing approval of Janssen’s Spravato (esketamine) CIII nasal spray to include treatment of symptoms …
Axsome’s late-stage study of experimental depression drug misses main trial goal
March 31, 2020Manufacturing and Production Depressive Disorder, MDD, depression, migraine
Axsome Therapeutics reported on Monday that its Phase 3 study of its experimental depression drug missed its main trial goal. …
NICE rejects Janssen’s esketamine nasal spray Spravato for treatment-resistant depression
January 28, 2020Manufacturing and Production, Sales and Marketing Janssen, NHS, NICE, Spravato, depression
Janssen’s Spravato (esketamine) nasal spray, derived from the party drug ketamine, has been turned down by NICE for NHS use …
European Commission authorises Janssen’s anti-depressant Spravato
December 23, 2019Sales and Marketing Janssen, MDD, Nasal Spray, TRD, depression, mental health
The European Commission has approved Janssen’s nasal spray Spravato (esketamine), which is used to treat major depressive disorder (MDD) that …
Oral contraceptive use as teenager linked to depression as an adult, study says
August 29, 2019Research and Development MDD, depression, hormones, oral contraceptives, psychiatry, psychology
Women who have used oral contraceptives as teenagers are more likely to experience depression later in life, according to a …
Janssen’s argues for the cost-effectiveness of Spravato in treatment-resistant depression
May 23, 2019Sales and Marketing FDA, Janssen, depression, major depressive disorder, pharma, treatment-resistant depression
Janssen has unveiled a new cost-effectiveness analysis for its recently FDA-approved nasal spray Spravato (esketamine) in the treatment of treatment-resistant …
New Phase 3 data backs up the efficacy of esketamine in treatment-resistant depression
May 21, 2019Manufacturing and Production, Research and Development, Sales and Marketing Spravato, depression, esketamine, pharma
New research has been published on the efficacy of esketamine in the treatment of depression, following its approval from the …
England’s antidepressant prescriptions double to 70m in a decade
March 29, 2019Medical Communications England, UK, antidepressants, anxiety, depression, pharma
Figures released by NHS Digital have revealed that prescriptions for antidepressants in the UK have risen to 70.9 million, almost …
Department of Veteran Affairs to offer Janssen’s esketamine to veterans with depression
March 21, 2019Medical Communications Jannsen, Spravato, VA, depression, esketamine, military, veteran affairs
The United States Department of Veteran Affairs (VA), the federal agency responsible for providing healthcare services to military veterans, is …
Latest content
FibroFind appoints Lee Borthwick as CEO
